GLOBUS MEDICAL INC
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
GMED$76.37+7.5%Stored close · as of Nov 9, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2025-03-31; filed 2025-05-08.
0001562762-25-000118
Item 1A. Risk FactorsCurrent report: 10-Q
Period ended 2025-06-30; filed 2025-08-07.
0001562762-25-000200
Item 1A. Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 12 previous paragraphs and 3 current paragraphs.
1 unchanged; 2 reworded; 0 added; 9 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
The current filing states there were no material changes to risk factors.
This is the filer’s own statement, not a conclusion from the comparison. Read its qualifications and the report it references.
Current filing’s statement
There have been no material changes to the risk factors set forth in Item 1A. “Risk Factors” of our 2024 Annual Report on Form 10-K filed on February 20, 2025 and our March 31, 2025 Quarterly Report on Form 10-Q filed on May 8, 2025.
Removed paragraphs (9)
Previous report
Tariff policies and potential countermeasures could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations.
Previous report
In April 2025, the U.S. began enacting the imposition of widespread and substantial tariffs on imports, with plans for additional tariffs to potentially be adopted in the future. We are unable to predict what additional actions, if any, may ultimately be taken by the U.S. or other governments with respect to tariffs or trade relations, which products may be subject to such actions (including subject to U.S. export control restrictions), or what actions may be taken by any other countries in retaliation, or the impact, if any, that any such policy changes could have on our business. The potential resultant impact of the imposition of these or any other new or increased tariffs on import markets could have an adverse effect on Globus’ results of operations, cash flow and financial condition.
Previous report
Integrating the Nevro business into Globus may be more difficult, costly or time-consuming than expected and Globus may fail to realize the anticipated benefits of the Nevro Merger, which may adversely affect our business results and negatively affect the value of our common stock.
Previous report
We have incurred and expect to incur non-recurring costs associated with the acquisition of Nevro, as well as transaction fees and other costs related to the Nevro Merger. Such costs include, among others, legal, accounting, investment banking and consulting fees.
Previous report
The success of the Nevro Merger will depend on, among other things, our ability to realize the anticipated benefits, synergies and efficiencies from integrating the Nevro business into Globus. If we are not able to successfully integrate Nevro’s business into Globus within the anticipated time frame, or at all, the anticipated synergies, efficiencies and other benefits of the Nevro Merger may not be realized fully, or at all, or may take longer to realize than expected. In addition, Globus may incur additional or unexpected costs in order to realize these benefits. Failure to achieve the expected synergies could significantly reduce the expected benefits associated with the Nevro Merger.
Previous report
An inability to realize the full extent of the anticipated benefits of the Nevro Merger, as well as any delays encountered in the integration process, could have an adverse effect upon the revenues, level of expenses and operating results of Globus, which may adversely affect the value of our common stock.
Previous report
The Company may also incur restructuring and integration costs in connection with the Nevro Merger. There are processes, policies, procedures, operations, technologies and systems that must be integrated in connection with the Nevro Merger and the integration of Nevro’s business into Globus. Although Globus expects that the elimination of duplicative costs, strategic benefits and additional income, as well as the realization of other efficiencies related to the integration of the businesses, may offset incremental transaction, merger-related and restructuring costs over time, any net benefit may not be achieved in the near term or at all. While
Previous report
Globus has assumed that certain expenses would be incurred in connection with the Nevro Merger, there are many factors beyond Globus’s control that could affect the total amount or the timing of the integration and implementation expenses.
Reworded paragraphs (2)
Previous wording
Risk factors that could cause our actual results to differ from our expectations and that could negatively impact our business, results of operations and financial condition are discussed in our 2024 Annual Report on Form 10-K filed on February 20, 2025. If any of these risks actually occur, our business, results of operations, financial condition and future growth prospects could be materially and adversely affected. You should carefully read and consider each of these risks, together with all of the other information set forth in this Quarterly Report on Form 10-Q. The risks and uncertainties described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also materially adversely affect our business, results of operations, financial condition and future growth prospects, and our stock price.
Current wording
Risk factors that could cause our actual results to differ from our expectations and that could negatively impact our business, results of operations and financial condition are discussed in our 2024 Annual Report on Form 10-K filed on February 20, 2025 and our March 31, 2025 Quarterly Report on Form 10-Q filed May 8, 2025. If any of these risks actually occur, our business, results of operations, financial condition and future growth prospects could be materially and adversely affected. You should carefully read and consider each of these risks, together with all of the other information set forth in this Quarterly Report on Form 10-Q. The risks and uncertainties described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also materially adversely affect our business, results of operations, financial condition and future growth prospects, and our stock price.
Previous wording
The following risk factors applicable to the Company as set forth in Item 1A. Risk Factors of our 2024 Annual Report on Form 10-K filed on February 20, 2025, has been added or updated.
Current wording
There have been no material changes to the risk factors set forth in Item 1A. “Risk Factors” of our 2024 Annual Report on Form 10-K filed on February 20, 2025 and our March 31, 2025 Quarterly Report on Form 10-Q filed on May 8, 2025.